Search research articles
Contact Us
Filters
Showing results (551-560 of 601) with videos related to
Page
of 61
Sort By:
Annals of Human Genetics
|
January 31, 2003
CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population
J A Cavanaugh, K E Adams, E J Quak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2020
Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Jonathan M Loree, Anthony Dowers, Dongsheng Tu, et al.
The Lancet. Gastroenterology & Hepatology
|
December 18, 2017
Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)
Michael G Penniment, Paolo B De Ieso, Jennifer A Harvey, et al.
The New England Journal of Medicine
|
November 16, 2007
Cetuximab for the treatment of colorectal cancer
Derek J Jonker, Chris J O'Callaghan, Christos S Karapetis, et al.
Neurology
|
April 17, 2013
Autosomal dominant vasovagal syncope: clinical features and linkage to chromosome 15q26
Karl Martin Klein, Catherine J Bromhead, Katherine R Smith, et al.
Brain : a Journal of Neurology
|
September 14, 2010
Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy
Manju A Kurian, Esther Meyer, Grace Vassallo, et al.
Cancer Medicine
|
October 16, 2018
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
Daniel Shepshelovich, Amanda R Townsend, Osvaldo Espin-Garcia, et al.
Journal of the National Cancer Institute
|
August 12, 2009
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial
Nicole Mittmann, Heather-Jane Au, Dongsheng Tu, et al.
The New England Journal of Medicine
|
October 24, 2008
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2024
Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, et al.
Page
of 61
Search research articles
Search
Showing results (551-560 of 601) with videos related to
Sort By:
Page
of 61
Annals of Human Genetics
|
January 31, 2003
CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population
J A Cavanaugh, K E Adams, E J Quak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2020
Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Jonathan M Loree, Anthony Dowers, Dongsheng Tu, et al.
The Lancet. Gastroenterology & Hepatology
|
December 18, 2017
Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)
Michael G Penniment, Paolo B De Ieso, Jennifer A Harvey, et al.
The New England Journal of Medicine
|
November 16, 2007
Cetuximab for the treatment of colorectal cancer
Derek J Jonker, Chris J O'Callaghan, Christos S Karapetis, et al.
Neurology
|
April 17, 2013
Autosomal dominant vasovagal syncope: clinical features and linkage to chromosome 15q26
Karl Martin Klein, Catherine J Bromhead, Katherine R Smith, et al.
Brain : a Journal of Neurology
|
September 14, 2010
Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy
Manju A Kurian, Esther Meyer, Grace Vassallo, et al.
Cancer Medicine
|
October 16, 2018
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
Daniel Shepshelovich, Amanda R Townsend, Osvaldo Espin-Garcia, et al.
Journal of the National Cancer Institute
|
August 12, 2009
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial
Nicole Mittmann, Heather-Jane Au, Dongsheng Tu, et al.
The New England Journal of Medicine
|
October 24, 2008
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2024
Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, et al.
Page
of 61